CMND Clearmind Medicine Inc.
Price Chart
Executive Summary
Clearmind Medicine announced that the Johns Hopkins IRB approved advancing its Phase I/II CMND-100 trial to Parts B and C, following successful completion of earlier stages. For a $2M market-cap pre-revenue biotech, this is a modest clinical milestone that de-risks the program incrementally but does not change the fundamental risk profile or cash runway.
Actionable Insight
This is a routine clinical milestone for a micro-cap biotech — IRB approvals for Phase I/II continuation are common and do not constitute a value inflection. Monitor for actual dosing data or safety readouts from Parts B/C, which would be more material. The company's extremely low share count (158K shares) means any equity offering would be highly dilutive — watch for capital raises.
Key Facts
- Johns Hopkins Medicine IRB granted approval to proceed with Parts B and C of the CMND-100 Phase I/II clinical trial for Alcohol Use Disorder
- The trial is titled 'A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and AUD Subjects: Parts A, B, and C'
- No financial terms, enrollment numbers, dosing data, or timeline for completion were disclosed
- Company had 158,076 common shares outstanding as of January 19, 2026, per the 20-F filed January 2026
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company with $2M market cap
Risk Factors
- No disclosed cash runway or financing plans — company may need to raise capital to fund Parts B and C
- Clinical-stage biotech with no approved products or revenue; any safety signal could halt the program
- Extremely low market cap ($2M) and share count (158K) make the stock highly volatile and susceptible to dilution
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-060791 |
| Document: ea029214102ex99-1.htm | 0001213900-26-060791 |
| Document: 0001213900-26-060791-index-headers.html | 0001213900-26-060791 |
| Document: 0001213900-26-060791-index.html | 0001213900-26-060791 |
| Document: 0001213900-26-060791.txt | 0001213900-26-060791 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
3
| $3.36 awaiting T+5 | awaiting T+5 | — | $3.34 (−0.60%) |
|
Jun 5, 2026
9d ago
|
Press Release
| $2.76 awaiting T+5 | awaiting T+5 | — | $3.34 (+21.01%) |
|
May 29, 2026
16d ago
|
6-K
| $3.58 $2.91 | ▼ −18.72% | ▼ −18.42% | $3.34 (−6.70%) |
|
May 29, 2026
16d ago
|
Press Release
| $3.58 $2.91 | ▼ −18.72% | ▼ −18.42% | $3.34 (−6.70%) |
|
May 26, 2026
19d ago
|
6-K
| $2.59 $3.17 | ▲ +22.39% | ▲ +21.31% | $3.34 (+28.96%) |
|
May 26, 2026
19d ago
|
Press Release
| $2.59 $3.17 | ▲ +22.39% | ▲ +21.31% | $3.34 (+28.96%) |
|
May 19, 2026
26d ago
|
6-K
| $2.36 $2.58 | ▼ −9.28% | ▼ −7.04% | $3.34 (−41.53%) |
|
May 19, 2026
26d ago
|
6-K
| $2.36 $2.58 | ▲ +9.28% | ▲ +7.04% | $3.34 (+41.53%) |
|
May 19, 2026
26d ago
|
Press Release
| $2.36 $2.58 | ▼ −9.28% | ▼ −7.04% | $3.34 (−41.53%) |
|
May 18, 2026
27d ago
|
6-K
| $2.36 $2.58 | ▼ −9.28% | ▼ −7.04% | $3.34 (−41.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access